Growing evidence supports the concept that in Alzheimer’s disease (AD), metabolic dysfunction, mediated by impairments in insulin and insulin-like growth factor (IGF) signaling [1–12], causes progressive deficits in brain glucose utilization, energy metabolism, cytoskeleton and myelin maintenance, and neuronal plasticity [13,14]. The gene discussed is INS; the disease is Alzheimer disease.